• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Team
  • News
EyeBio

EyeBio

  • Business Development
  • Contact

Back to Team

Jonathan Prenner, M.D.

Chief Medical Officer

LinkedIn

Jonathan joined EyeBio as Chief Medical Officer. A noted retina specialist with several leadership positions in the field of vitreoretinal surgery, he is currently Chairman of the Department of Ophthalmology at Rutgers Robert Wood Johnson Medical School, where he serves as Clinical Professor. For the past fifteen years he has held the positions of Review Article Section Editor and Assistant Editor for the standard scientific journal for the field, RETINA: The Journal of Retinal and Vitreous Diseases. An active researcher, Jonathan has published more than 95 peer-reviewed papers, and he routinely lectures on his original research and the development of new approaches to vitreoretinal diseases at major scientific meetings.

Jonathan has an extensive history of working with biotechnology startups. He has been a member of the scientific advisory boards of Acuity Pharmaceuticals and OPKO and has served on the data safety monitoring boards of Neurotech and Clearside Bio. He has also had long-term strategic consulting relationships with Neovista, Ophthotech, and Panoptica.

Jonathan received his B.A. from the University of Pennsylvania and his Medical Doctor degree from the State University of New York at Stony Brook, where he was accepted into the Alpha Omega Alpha Honor Society. Jonathan then returned to the University of Pennsylvania’s Scheie Eye Institute for residency training and completed his vitreoretinal fellowship at William Beaumont Hospital in Royal Oak, Mich. He has been a practicing clinician since 2004.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Team
  • News
  • Business Development
  • Contact